Adult Pompe disease: Analysis of 13 patients.
Enfermedad de Pompe del adulto: análisis de 13 pacientes.
Acid alfa-glucosidase
Alfa glucosidasa ácida
Enfermedad de Pompe de inicio tardío
Enzyme replacement therapy
GAA gen
Gen GAA
Late onset Pompe disease
Terapia enzimática sustitutiva
Tratamiento
Treatment
Journal
Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377
Informations de publication
Date de publication:
17 Aug 2024
17 Aug 2024
Historique:
received:
25
03
2024
revised:
16
05
2024
accepted:
16
05
2024
medline:
19
8
2024
pubmed:
19
8
2024
entrez:
18
8
2024
Statut:
aheadofprint
Résumé
Pompe Disease (PD) is a lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA), primarily manifesting as a progressive myopathy with early respiratory involvement. Enzyme replacement therapy (ERT) is available since 2006. We describe 13 patients with partial GAA deficiency, followed at Hospital 12 de Octubre, 8 of whom were receiving treatment. 8 patients exhibit symptoms, all with late onset. They display axial and proximal weakness predominantly in the lower limbs but maintain autonomous gait. Five patients require non-invasive mechanical ventilation due to respiratory insufficiency. All symptomatic patients receive ERT, and in 7/8 (87.5%), there is a decline in motor and pulmonary function after an average of 8.25 years of treatment (baseline and post-treatment FVC and 6MWT mean 86.6% vs 70.8% and 498 vs 430 meters, respectively). Not all patients with partial GAA deficiency experience symptoms of PD, and symptomatic patients, despite ERT with recombinant alpha-glucosidase, mostly experience a gradual decline in motor and respiratory function.
Identifiants
pubmed: 39155212
pii: S0025-7753(24)00399-3
doi: 10.1016/j.medcli.2024.05.022
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier España, S.L.U. All rights reserved.